News 2015

Cognition Therapeutics Commences Clinical Trials in Melbourne

Scale Angels investee company Cognition Therapeutics commences clinical trials in Melbourne Cognition Therapeutics Inc. (CogRx), a privately held pharmaceutical company focused on discovering and developing disease-modifying therapies for Alzheimer’s and related neurodegenerative diseases, announced today that it has commenced Phase 1 clinical studies in Melbourne. This study will examine the safety and pharmacokinetics of the …

Cognition Therapeutics Commences Clinical Trials in Melbourne Read More »

Cognition Therapeutics Completes Oversubscribed $12 Million Series B Financing

PITTSBURGH, Sept. 8, 2015 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), a privately held pharmaceutical company focused on discovering and developing disease-modifying therapies for Alzheimer’s and related neurodegenerative diseases, announced today that it has completed a Series B preferred stock financing totaling $12 million. Golden Seeds led the investment syndicate, which included, Bios Memory SPV1, Cowtown Angels, Scale Investors, Dolby Family Ventures, Maine …

Cognition Therapeutics Completes Oversubscribed $12 Million Series B Financing Read More »

Scroll to Top